Rani Therapeutics
RANI
64 hedge funds and large institutions have $60.5M invested in Rani Therapeutics in 2025 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 15 increasing their positions, 0 reducing their positions, and 9 closing their positions.
4,218% more call options, than puts
Call options by funds: $12.7M | Put options by funds: $293K
2,902% more capital invested
Capital invested by funds: $2.02M → $60.5M (+$58.5M)
311% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 9
68% more funds holding
Funds holding: 38 → 64 (+26)
37.38% more ownership
Funds ownership: 8.57% → 45.95% (+37%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$12.8M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$12.8M |
| 3 |
AIC
AWM Investment Company
New York
|
+$9.81M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.37M |
| 5 |
LP
Longaeva Partners
Chicago,
Illinois
|
+$3.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$683K |
| 2 |
HF
HRT Financial
New York
|
-$56K |
| 3 |
IAS
Insigneo Advisory Services
Miami,
Florida
|
-$23.7K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$22K |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
-$16.4K |
RANI Hedge Fund Activity: Q4 2025 in Review
64 of the 8,275 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q4 2025, worth a combined $60.5M — up 2,902% from $2.02M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new RANI positions and 9 closed out — a net gain of 28 holders — while 15 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $12.8M. The largest seller was Citadel Advisors, exiting entirely with an estimated $683K sold.
- 64 institutional investors held Rani Therapeutics (RANI) as of Q4 2025, up from 38 in Q3 2025.
- Funds reported $60.5M of Rani Therapeutics stock for Q4 2025, up 2,902% quarter-over-quarter.
- 37 funds opened new Rani Therapeutics positions in Q4 2025 and 9 closed out, a net change of +28 holders.
- The largest Rani Therapeutics buyer in Q4 2025 was RA Capital Management, an estimated $12.8M added.
- The largest Rani Therapeutics seller in Q4 2025 was Citadel Advisors, an estimated $683K sold.
Based on aggregated 13F filings for Q4 2025.